Articles
Although the role of biosimilars in the treatment of patients with cancer has been under review by payers and providers for several years, there remains conflicting application regarding policy and strategy. Read More ›
It is estimated that 350 million people worldwide use biologics on a regular basis to treat their medical conditions. Read More ›
Biologic drugs, which include therapeutic proteins and monoclonal antibodies, are large complex molecules typically manufactured in genetically engineered organisms. Read More ›
In recent years, biologics have increasingly been used for the treatment and supportive care of patients with various serious illnesses, including cancer. Read More ›
On July 1, 2021, 28 patient advocacy groups submitted a letter demonstrating their support for H.R. 2815, also known as the Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act, which aims to increase Medicare reimbursement for health systems that prescribe biosimilars to patients. Read More ›
Rapid adoption of FDA-approved biosimilars is feasible, measurable, and scalable—and pharmacists should lead the charge, according to data presented at the virtual 2021 American Society of Clinical Oncology Quality Care Symposium. Read More ›
Biosimilars have the potential to create a more sustainable healthcare environment by offering substantial cost-savings and expanding patient access to life-saving therapies. Read More ›
By Anne Rowe
The advent of biologic drugs has had a significant impact on the management of patients with cancer. However, the high costs associated with these agents can hinder treatment access for many patients and place a significant burden on healthcare systems. Read More ›
On September 20, 2021, the FDA announced the availability of its revised final guidance for industry on biosimilar development and the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). Read More ›